Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanxi Bethune Hospital CAR-T cell therapy
- Development stage
- Unknown
- Lead developer
- Shanxi Bethune Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Shanxi Bethune Hospital CAR-T cell therapy is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of relapsed or refractory hematological malignancies. The therapy involves the ex vivo genetic modification of a patient's autologous T cells to express a chimeric antigen receptor designed to recognize and eliminate malignant cells. Following expansion to a therapeutic dose, the modified cells are re-infused into the patient, typically after a non-myeloablative lymphodepletion chemotherapy regimen. It is currently being evaluated in a Phase 2/3 clinical trial (NCT06238336) in China to assess safety and efficacy across various hematologic tumors. Specific details regarding the target antigen (e.g., CD19, BCMA) and the specific CAR construct have not been publicly disclosed.
- Other names
- CAR-T cell therapy (Shanxi Bethune Hospital)
Beyond the preview
Go deeper on Shanxi Bethune Hospital CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanxi Bethune Hospital CAR-T cell therapy.